Zacks Investment Research on MSN

JNJ's bladder cancer therapy meets key goal in early-stage study

Johnson & Johnson JNJ reported positive results from an early-stage study evaluating its investigational intravesical drug-releasing system with erdafitinib (Erda-iDRS) in patients with ...
CURE

New Approach May Reduce Recurrence in Muscle-Invasive Bladder Cancer

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...